Skip to main content
Erschienen in:

15.01.2024 | Original Article

Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC)

verfasst von: Anjali Mishra, Shravan Kumar Mishra, Vikram Sharanappa, Narendra Krishnani, Niraj Kumari, Gaurav Agarwal

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Molecular sub-characterization of triple-negative breast cancer (TNBC) has great therapeutic and possibly prognostic implications. The primary aim of this study was to investigate the incidence of luminal androgen receptor (LAR) subtype of TNBC and secondary aims were sub-categorization and clinico-pathologic correlation of LAR breast cancers. Retrospective study (January 2008 and 31st of December 2018) consisting of 157 TNBC patients. Androgen receptor (AR) expression was measured by immunohistochemical analysis. One percent cutoff was set as a positive expression. Sub-categorization was done on the basis of EGFR (> 15% of tumor cells) and Ki-67 expression (low- < 11%, intermediate- 11–20%, and high- > 21%). AR expression was correlated with various clinico-pathologic features and outcomes of the patients. The incidence of AR expression in TNBC was 24.8%. Considering different thresholds of > 5%, > 10%, and > 20% immunostaining, the incidence of AR positivity was 18.4, 15.2, and 11.5% respectively. The incidence of Ki-67 (p = 0.89) and EGFR (p = 0.643) expression did not differ significantly in AR-positive and -negative TNBC. Based on EGFR expression 19, 67 and 14% patients were categorized as low, intermediate, and high risk respectively. Low-risk (p ≤ 0.001) and low-grade (p = 0.014) tumors were more likely to have > 10% AR expression. Clinico-pathological profile, response to neoadjuvant chemotherapy, disease-free survival (p = 0.458), and overall survival (p = 0.806) did not significantly differ between AR expressing and negative TNBC. On multivariate analysis, only tumor staging was a significant predictor of survival (p = 0.012) and AR expression of > 10% revealed a trend towards improved survival (p = 0.07). When considering only AR-positive TNBC, AR expression of > 10% (p = 0.038), distant metastases (p = 0.003), and EGFR status (p = 0.024) were significantly associated with survival. AR expression does not seem to very strongly correlate with prognosis in TNBC and further studies could focus more on its predictive role in deciding anti-androgen therapy.
Literatur
10.
Zurück zum Zitat Mirzania M (2016) Approach to the triple negative breast cancer in new drugs area. Int J Hematol Oncol Stem Cell Res 10(2):115–119PubMedPubMedCentral Mirzania M (2016) Approach to the triple negative breast cancer in new drugs area. Int J Hematol Oncol Stem Cell Res 10(2):115–119PubMedPubMedCentral
15.
Zurück zum Zitat Luo X, Shi YX, Li ZM, Jiang WQ (2010) Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 29(6):585–590CrossRefPubMed Luo X, Shi YX, Li ZM, Jiang WQ (2010) Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 29(6):585–590CrossRefPubMed
18.
Zurück zum Zitat Rampurwala M, Wisinski KB, O’Regan R (2016) Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol 4:186–193 Rampurwala M, Wisinski KB, O’Regan R (2016) Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol 4:186–193
23.
Zurück zum Zitat Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arc Pathol Lab Med 124(7):966–978CrossRef Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arc Pathol Lab Med 124(7):966–978CrossRef
24.
Zurück zum Zitat Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ et al (2012) The growth response to androgen receptor signaling in ER-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res 9:14 Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ et al (2012) The growth response to androgen receptor signaling in ER-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res 9:14
30.
Zurück zum Zitat Mirzania M (2016) Approach to the triple negative breast cancer in new drugs area. Int J Hematol Oncol Stem Cell Res 10(2):115–119PubMedPubMedCentral Mirzania M (2016) Approach to the triple negative breast cancer in new drugs area. Int J Hematol Oncol Stem Cell Res 10(2):115–119PubMedPubMedCentral
36.
Zurück zum Zitat Hu R, Dawood S, Holmes MD et al (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17(7):1867–1874CrossRefPubMedPubMedCentral Hu R, Dawood S, Holmes MD et al (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17(7):1867–1874CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Choi JE, Kang SH, Lee SJ, Bae YK (2015) Androgen receptor expression predicts decreased survival in early- stage triple-negative breast cancer. Ann Surg Oncol 22(1):82–89CrossRefPubMed Choi JE, Kang SH, Lee SJ, Bae YK (2015) Androgen receptor expression predicts decreased survival in early- stage triple-negative breast cancer. Ann Surg Oncol 22(1):82–89CrossRefPubMed
38.
Zurück zum Zitat Lehmann-Che J, Hamy AS, Porcher R et al (2013) Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 15(3):R37CrossRefPubMedPubMedCentral Lehmann-Che J, Hamy AS, Porcher R et al (2013) Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 15(3):R37CrossRefPubMedPubMedCentral
Metadaten
Titel
Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC)
verfasst von
Anjali Mishra
Shravan Kumar Mishra
Vikram Sharanappa
Narendra Krishnani
Niraj Kumari
Gaurav Agarwal
Publikationsdatum
15.01.2024
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 2/2024
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-024-01877-2

Neu im Fachgebiet Chirurgie

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Kein Unterschied bei inadäquaten Schocks zwischen ICD-Typen

Inadäquate Schockabgaben sind ein unerwünschter Effekt der Therapie mit implantierbaren Kardioverter-Defibrillatoren. Subkutanen Geräten haftet dabei der Ruf an, dafür besonders anfällig zu sein. Die PRAETORIAN-Forschungsgruppe ist dem nachgegangen.

DCIS: Ist ein Verzicht auf eine Operation möglich?

Die COMET-Studie zeigt, dass aktives Monitoring bei Patientinnen mit duktalem Carcinoma in situ (DCIS) hinsichtlich der kumulativen Zwei-Jahres-Rate an ipsilateralen invasiven Karzinomen der leitliniengerechten Standardbehandlung nicht unterlegen ist. Dennoch wird von einem Verzicht auf eine Operation abgeraten, wie in einem begleitenden Editorial betont wird.

Soll man bei Cholezystektomie routinemäßig cholangiografieren?

Eine US-Studie scheint den Befürwortern einer routinemäßigen intraoperativen Cholangiografie im Rahmen einer Cholezystektomie Recht zu geben. Die Studienkommentatoren in JAMA Surgery sparen jedoch nicht mit Kritik.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.